At JP Morgan 2025, pharmaphorum editor-in-chief Jonah Comstock spoke with Ryan Spencer, whose company Dynavax technologies is ...

An inhaled gene therapy for cystic fibrosis developed by Boehringer Ingelheim is due to start clinical testing shortly, hoping to become a first-in-class treatment for the genetic disorder.

Blincyto's label has gradually been extended since 2014, and in December the MHRA approved it as the first immunotherapy for ...

A proposed merger of the UK's Poolbeg Pharma with Austrian biotech Hookipa has been called off after the latter abruptly ...

The week has ended with a flurry of M&A in the drug industry, with Cosette Pharmaceuticals agreeing to buy Australia's Mayne ...

At two Senate confirmation hearings, Kennedy played down his well-publicised questioning of the safety of childhood vaccines ...

After 2024, which saw a steady recovery by the life sciences industry, it looks like 2025 is set to be a year of change and development, particularly in clinical trials. The good news is that ...

I’ve worked in clinical trials for twenty years. For most of that time, the core processes and challenges have been fairly consistent, with incremental improvements along the way. That’s all ...

AstraZeneca has unveiled plans to invest around $570 million in Canada and add around 700 new jobs, describing the county as a "growing global hub" for clinical trials. The C$820 million ...

The healthcare industry experienced a rollercoaster of a year in 2024, with pharmacy benefits undergoing significant shifts. Rising drug costs, advancements in medication technology, and changing ...

Social media is a hub of opinion, argument, and advocacy that traverses a virtually endless spectrum. Among the most active voices in this environment are healthcare professionals (HCPs).

Rare disease treatment poses distinct challenges for physicians, patients, caregivers, and pharma companies. With many of these conditions lacking approved treatments, the standard care often ...